Background-Exercise training reduces the symptoms of chronic heart failure. Which exercise intensity yields maximal beneficial adaptations is controversial. Furthermore, the incidence of chronic heart failure increases with advanced age; it has been reported that 88% and 49% of patients with a first diagnosis of chronic heart failure are Ͼ65 and Ͼ80 years old, respectively. Despite this, most previous studies have excluded patients with an age Ͼ70 years. Our objective was to compare training programs with moderate versus high exercise intensity with regard to variables associated with cardiovascular function and prognosis in patients with postinfarction heart failure. Methods and Results-Twenty-seven patients with stable postinfarction heart failure who were undergoing optimal medical treatment, including -blockers and angiotensin-converting enzyme inhibitors (aged 75.5Ϯ11.1 years; left ventricular [LV] ejection fraction 29%; V O 2peak 13 mL · kg Ϫ1 · min
Simvastatin and ezetimibe did not reduce the composite outcome of combined aortic-valve events and ischemic events in patients with aortic stenosis. Such therapy reduced the incidence of ischemic cardiovascular events but not events related to aortic-valve stenosis. (ClinicalTrials.gov number, NCT00092677.)
Background—
Retrospective studies have suggested that patients with a low transvalvular gradient in the presence of an aortic valve area <1.0 cm
2
and normal ejection fraction may represent a subgroup with an advanced stage of aortic valve disease, reduced stroke volume, and poor prognosis requiring early surgery. We therefore evaluated the outcome of patients with low-gradient “severe” stenosis (defined as aortic valve area <1.0 cm
2
and mean gradient ≤40 mm Hg) in the prospective Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study.
Methods and Results—
Outcome in patients with low-gradient “severe” aortic stenosis was compared with outcome in patients with moderate stenosis (aortic valve area 1.0 to 1.5 cm
2
; mean gradient 25 to 40 mm Hg). The primary end point of aortic valve events included death from cardiovascular causes, aortic valve replacement, and heart failure due to aortic stenosis. Secondary end points were major cardiovascular events and cardiovascular death. In 1525 asymptomatic patients (mean age, 67±10 years; ejection fraction, ≥55%), baseline echocardiography revealed low-gradient severe stenosis in 435 patients (29%) and moderate stenosis in 184 (12%). Left ventricular mass was lower in patients with low-gradient severe stenosis than in those with moderate stenosis (182±64 versus 212±68 g;
P
<0.01). During 46 months of follow-up, aortic valve events occurred in 48.5% versus 44.6%, respectively (
P
=0.37; major cardiovascular events, 50.9% versus 48.5%,
P
=0.58; cardiovascular death, 7.8% versus 4.9%,
P
=0.19). Low-gradient severe stenosis patients with reduced stroke volume index (≤35 mL/m
2
; n=223) had aortic valve events comparable to those in patients with normal stroke volume index (46.2% versus 50.9%;
P
=0.53).
Conclusions—
Patients with low-gradient “severe” aortic stenosis and normal ejection fraction have an outcome similar to that in patients with moderate stenosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.